Clinical trials
Human Papillomavirus (HPV) clinical trials
Below are recruiting human papillomavirus (hpv) clinical trials, each written for real people, not researchers. We’re tracking 64 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06550531Recruiting
HPV and IVF/ICSI success study
This study looks at whether carrying human papillomavirus (HPV) affects the chances of success with IVF or ICSI (types of fertility treatments). It may help explain why some treatments work better than others.
BrestAges 25–38 - NCT06544720RecruitingPhase 1
SCG142 TCR-T cell therapy for HPV-related cancers
This trial tests a new treatment called SCG142 TCR-T cells for cancers caused by HPV. The therapy uses your own immune cells to fight the tumor. It may help if other treatments haven't worked or are not available.
Qingdao, ShandongAges 18 years+ - NCT06815939Recruiting
A Simple, Lab-Free Test for Cervical Cancer
This trial is testing a new, low-cost, lab-free screening test for cervical cancer. The goal is to see if it can detect early signs of cancer without needing a doctor's visit or a lab — making it easier for women to get screened.
San SalvadorAges 30–59 - NCT07698886RecruitingPhase 2
Laser plus Geniwa gel for recurring genital warts
This trial tests whether adding a special gel (Geniwa gel) to standard laser treatment helps prevent genital warts from coming back. It may be an option for people who have already tried laser treatment but their warts returned.
Hanoi, None (International)Ages 18 years+ - NCT05539638Recruiting
Testing blood DNA for head and neck squamous cancer
This study looks at how tumor DNA found in a blood sample (a “DNA signal”) relates to head and neck cancer in the oropharynx. It may help doctors understand disease status and improve how they monitor treatment, for both HPV-positive and HPV-negative cancers.
Dundee, DD2 1SGAges 18 years+ - NCT05686226RecruitingPhase 2
Trial tests immune cells targeting HPV-16 cancers
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Bethesda, MarylandAges 18 years+ - NCT06254846Recruiting
Urine test for HPV cervical cancer screening
This study tests if a urine sample can replace a cervical swab for HPV testing during cervical cancer screening. If it works, it could make screening easier and less uncomfortable.
Saint-EtienneAges 30–65 - NCT07033091Recruiting
HPV screening study for healthy adults 40 and older
This study checks healthy adults aged 40+ for HPV in the mouth using a simple gargle rinse. It aims to see if this can help find early signs of oropharyngeal cancer.
BrnoAges 40 years+ - NCT07290621RecruitingPhase 2
Toripalimab with standard treatment for HPV-positive throat cancer
This study tests adding a new immunotherapy drug (toripalimab) to standard chemo for HPV-positive throat cancer. It aims to see if this combination works better than chemo alone for patients whose cancer has spread to nodes but not to other parts of the body.
Chicago, IllinoisAges 18 years+ - NCT06926062Recruiting
Improving HPV vaccine communication in pharmacies
This study looks at whether training pharmacy staff in communication and vaccination workflows can improve HPV vaccine recommendations and uptake. If you are a parent or guardian of a child aged 9–17 who has not yet completed the HPV vaccine series, you may be eligible to participate.
University Park, PennsylvaniaAges 18 years+ - NCT05365048Recruiting
Promoting HPV vaccine visits in kids ages 9–12
This study looks at whether getting a provider recommendation helps more parents bring children ages 9–12 in for HPV vaccination. It may help increase vaccination uptake in pediatric clinics.
Pasadena, CaliforniaAges 21–70 - NCT06007092RecruitingPhase 1/Phase 2
HPV vaccine trial for oropharyngeal cancer patients
This trial tests a therapeutic vaccine for people with HPV16-positive oropharyngeal cancer who have finished curative treatment and are free of disease. The vaccine aims to help the immune system prevent the cancer from coming back.
VillejuifAges 18 years+ - NCT06808776Recruiting
Stories to prevent HPV cancers
This trial tests if sharing stories can help parents decide to get their child the HPV vaccine. It is for parents of children ages 9 to 12 who have not yet started the HPV shot series.
Hershey, PennsylvaniaAges 18 years+ - NCT06610773RecruitingPhase 1/Phase 2
Stem cell treatment for high-risk HPV infection
This trial tests whether umbilical cord stem cells can help clear a persistent high-risk HPV infection. It is for women aged 25 to 60 who have had HPV for a while and have not been treated with other HPV drugs recently.
Shanghai, Shanghai MunicipalityAges 25–60 - NCT06997094RecruitingPhase 1
Decitabine plus standard therapy for HPV-negative head and neck cancer
This trial tests whether adding the drug decitabine to standard treatment (surgery and possibly radiation) can help people with a type of head and neck cancer not caused by HPV. You would receive decitabine before surgery, and then continue with standard care after.
Jacksonville, FloridaAges 18 years+ - NCT07179315RecruitingPhase 2
Immunotherapy Study for HPV-Positive Head and Neck Cancer
This trial compares two different immunotherapy approaches for people with HPV-positive oropharyngeal cancer who have completed initial treatment like surgery, radiation, or chemotherapy. The goal is to see which option works better to keep the cancer from coming back, and eligibility is determined by a special blood test that detects HPV DNA.
Chicago, IllinoisAges 18 years+ - NCT05026138Recruiting
Study of severe HPV disease and why it keeps coming back
This study follows people with severe or hard-to-treat HPV-related conditions (and some closely related partners/household contacts) to learn how the virus causes illness and how the immune system responds. It may help doctors better predict who will develop severe disease and guide future treatments.
Bethesda, MarylandAges 3–100 - NCT07550010Recruiting
Digital Screening for Cervical Cancer in Cameroon
This study tests a new digital imaging method to help screen women for cervical cancer risk in Cameroon. It may help catch cervical problems earlier using easier-to-read pictures of the cervix.
YaoundéAges 25–50 - NCT06650956Recruiting
HPV vaccine and health education for teens in Laos
This trial offers HPV vaccination and sexual health education to 10-13 year old students and out-of-school youth in Laos. It aims to improve health knowledge and vaccination rates.
Muang Sing, ProvinceAges 10–13 - NCT07104240Recruiting
Improving HPV vaccination for preteens ages 9-12
This study tests a program designed to help primary care practices increase HPV vaccination rates among adolescents aged 9 to 12 who haven't yet been vaccinated. It aims to find out if providing practices with resources and support can lead to more kids getting the HPV vaccine.
Atlanta, GeorgiaAges 9 years+ - NCT05774561Recruiting
Using blood tests to monitor HPV-related cancer treatment
This study checks whether “liquid biopsies” (blood tests that look for cancer-related signals) can help monitor how HPV-related cancers respond to treatment. It may help doctors spot changes earlier during care.
OlomoucAges 18–99 - NCT05262010RecruitingPhase 3
HPV vaccine study for Chinese women, ages 9–45
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
Hechi, GuangxiAges 18–45 - NCT07301905Recruiting
HPV vaccine study for parents in Flint, MI
This study tests a culturally tailored health message to see if it helps parents feel more open to the HPV vaccine for their daughters. It focuses on families in Flint whose daughters have not yet received the vaccine.
Flint, MichiganAges 18 years+ - NCT04901351Recruiting
Genetic testing for persistent high-risk HPV after treatment
This study uses a detailed DNA test to look for high-risk HPV in people with long-lasting (chronic) infection after treatment or with return of abnormal cells. It may help improve how clinicians monitor high-risk HPV and decide next steps.
ToulouseAges 18 years+
Hear when a new Human Papillomavirus (HPV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for human papillomavirus (hpv)?
- Yes. Clin2 currently lists 64 recruiting human papillomavirus (hpv) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a human papillomavirus (hpv) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a human papillomavirus (hpv) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.